G Model
CCLET-2576; No. of Pages 4
2
S. Rostamizadeh et al. / Chinese Chemical Letters xxx (2013) xxx–xxx
Ar
O
N
N
N
Nano Fe3O4
CN
NH2
+
+
Ar
H
100 oC
H2N
NH2Cl
N
1
4
3
2
Scheme 1. Reaction used for the synthesis of pyrimidine-5-carbonitrile derivatives.
2.1. General procedure for the synthesis of 4a–4m
compound that prevented the bacteria growth (<99%) was
designated as the minimum inhibitory concentration (MIC).
Growth was present in the medium control but was absent from
the inoculum control.
Malonitrile (1 mmol), aldehyde (1 mmol), benzamidine hydro-
chloride (1 mmol), magnetic nano Fe3O4 (0.06 g), were ground and
placed in a test tube. The reaction mixture was stirred under
heating for 1–1.5 h at 100 8C and monitored by TLC, (EtOAc/
petroleum ether, 1:2). After the completion of the reaction, the
reaction mixture was cooled to ambient temperature, EtOAc was
added, and the nano Fe3O4 was separated using an external
magnet, then the mixture was concentrated in vacuo to obtain a
solid product. The residues were further purified by crystallization
from EtOH. It is worth to mention that the nano Fe3O4 could be
reused three times without any significant loss of activity.
3. Results and discussion
Initially, aromatic aldehyde 1, malononitirile 2, and benzami-
dine hydrochloride 3, were mixed and heated in the presence of
magnetic Fe3O4 nanoparticles as a catalyst under solvent-free
conditions at 100 8C (Scheme 1, Table 1). The products 4a–m were
all prepared with excellent yields at 100 8C in 1–1.5 h. Both
aromatic aldehydes with electron donating substituents (Table 1,
entries 7 and 13) and electron-withdrawing substituents (Table 1,
entries 6, 9 and 10) showed significant reactivity in this process.
Then, 6-amino-4-(4-chlorophenyl)-2-phenylpyrimidine-5-car-
bonitrile (1 mmol) (Table 1, entry 2, 4b), hydrazine hydrate (1 mL)
and EtOH (5 mL) were mixed and refluxed for 8 h. The reaction was
completed and only one new spot appeared on the TLC plate. After
aqueous work-up, a pure pale yellow solid was obtained from the
reaction mixture whose full characterization by spectroscopic
methods (IR, 1H NMR, 13C NMR, and mass spectra) revealed that
pyrazolo[3,4-d]pyrimidine 5b was obtained. In order to determine
the amount of hydrazine needed in this process, the reaction of
pyrimidine 4b was performed using 0.5 mL of hydrazine hydrate
and the same product was again obtained.
2.2. General procedure for the synthesis of 5a–5i
To a solution of 4-amino-6-aryl-2-phenyl pyrimidine-5-carbo-
nitrile derivatives (1 mmol) in EtOH (5 mL) was added hydrazine
hydrate (0.5 mL) and the mixture was heated under reflux. After
the completion of the reaction (monitored by TLC, EtOAc:
petroleum ether, 4:1) the reaction mixture was cooled to ambient
temperature and water (10 mL) was added. The solid materials
were filtered off and filtrate was concentrated and recrystallized
from ethanol.
Selected analytical data: 3-Amino-6-(4-chlorophenyl)-2-phenyl-
pyrazolo[3,4-d]pyrimidine (5b): Pale yellow powder; mp: 267 8C; IR
(KBr, cmÀ1):
n d
3449, 3325, 3307; 1H NMR (300 MHz, DMSO-d6):
However, using 0.065 mL (1 mmol) of hydrazine hydrate did
not result in the formation of product 5b and only the starting
material was recovered. So, the amount of 0.5 mL was chosen as
the optimal amount of hydrazine hydrate for each mmol of
pyrimidine derivatives. In the next step a model reaction (Scheme
1, Ar = 4-Cl–Ph) was performed in different solvents under
different conditions and the results showed that using EtOH as
solvent under reflux is the best condition. In order to examine the
scope and generality of this protocol for the synthesis of other
fused pyrazolo[3,4-d]pyrimidine derivatives, the pyrimidine deri-
vatives shown in Table 1 were also subjected to this process
12.82 (s, 1H, NH), 8.48–8.49 (m, 2H), 8.04–8.07 (d, 2H, J = 8.3 Hz),
7.66–7.69 (d, 2H, J = 8.3 Hz), 7.51–7.53 (m, 3H), 5.19 (s, 2H, NH2);
13C NMR (75 MHz, DMSO-d6):
d 159.9, 159.8, 156.1, 147.8, 137.6,
136.0, 135.3, 131.2, 130.6, 128.8, 128.6, 128.1, 100.7; MS (m/z): 321
(54); Anal. Calcd. for C17H12ClN5: C, 63.46; H, 3.76; Cl, 11.02; N,
21.77; Found: C, 63.58; H, 3.75; N, 21.65. 3-Amino-6-(3-amino-
phenyl)-2-phenylpyrazolo[3,4-d]pyrimidine (5g): Pale yellow pow-
der; mp: 311.5 8C; IR (KBr, cmÀ1):
n
3430, 3416, 3341; 1H NMR
(300 MHz, DMSO-d6): 12.00 (s, NH, br), 8.47–8.50 (m, 2H), 7.50–
d
7.52 (m, 3H), 7.23–7.28 (m, 1H), 7.13 (s, 1H), 7.00–7.03 (d, 1H,
J = 7.5 Hz), 6.77–6.80 (d, 1H, J = 7.4 Hz), 5.42 (s, 2H, NH2), 5.09 (s,
2H, NH2); 13C NMR (75 MHz, DMSO-d6):
d 162.1, 160.0, 155.8,
149.2, 147.6, 138.0, 137.7, 130.4, 129.3, 128.5, 128.0, 116.1, 115.7,
113.7,100.4; MS (m/z): 302 (100), 301 (64); Anal. Calcd. for
Table 1
Synthesis of pyrimidines 4a–m under solvent free conditions catalyzed by magnetic
C
17H14N6: C, 67.54; H, 4.67; N, 27.80; Found: C, 67.47; H, 4.56; N,
Fe3O4 nanocatalyst.
28.18.
Entry
Product
Ar
Yielda (%)
Mp (8C)
Lit. mp (8C)
1
2
4a
4b
4c
4d
4e
4f
Ph
98
96
94
96
96
98
96
96
96
96
90
95
95
214
210–212 [15]
222 [15]
236[14]
–
2.3. Determination of minimum inhibitory concentration (MICs)
4-Cl–Ph
222
3
4-Br–Ph
234–236
231–234
200–202
299–300
211
The MICs were assayed by the tube dilution test method,
introduced by National Committee for Clinical Laboratory Stan-
dards (NCCLS). A serial of dilutions of tested compounds (final
4
2,3-diCl–Ph
2-Cl–Ph
5
196 [16]
–
6
4-CN–Ph
4-Me–Ph
2,4-diCl–Ph
3-NO2–Ph
4-NO2–Ph
3-indolyl
4-CH3CONH–Ph
4-MeO–Ph
7
4g
4h
4i
210 [15]
170–17 [18]
–
concentration of 300–0.8
mmol/L) were added to the tested
8
174
bacteria in Mueller–Hinton broth (0.5 mL) in 24-well plates and
were incubated at 37 8C for 24 h (5 Â 105 CFU/mL). After sufficient
amount of incubation (24 h), the wells were examined for turbidity
as an indicator for growth of the bacteria. For further confirmation,
an aqueous solution of 2,3,5-triphenyltetrazolium chloride (0.5%;
9
201–202
215–217
230–232
245
10
11
12
13
4j
215 [16,17]
–
4k
4l
243–244 [17]
213 [15]
4m
213
a
100
m
L) was added to the wells. The lowest concentration of the
Isolated yield.
Please cite this article in press as: S. Rostamizadeh, et al., A novel and efficient synthesis of pyrazolo[3,4-d]pyrimidine derivatives and